Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure

Dr Chiara Sartor - University of Bologna, Bologna, Italy
Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure ( Dr Chiara Sartor - University of Bologna, Bologna, Italy )
20 Jun 2026

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma

Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA
DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma ( Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA )
20 Jun 2026

Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma

Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil
Favezelimab plus pembrolizumab improves progression-free survival in PD-1-refractory classic Hodgkin lymphoma ( Dr Guilherme Perini - Hospital Israelita Albert Einstein, São Paulo, Brazil )
19 Jun 2026

First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma

Dr Ying Huang - CEO, Legend Biotech
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma ( Dr Ying Huang - CEO, Legend Biotech )
19 Jun 2026

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis

Prof Ashutosh Wechalekar - University College London Hospitals, London, UK
Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis ( Prof Ashutosh Wechalekar - University College London Hospitals, London, UK )
19 Jun 2026

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Prof Liang Wang - Beijing Tongren Hospital, Beijing, China
CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )
19 Jun 2026

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA
Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )
18 Jun 2026

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany
ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )
18 Jun 2026

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA
Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )
18 Jun 2026

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis ( Prof Claire Harrison - Guy’s and St Thomas’ NHS Foundation Trust, London, UK )
18 Jun 2026

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding

Prof David Kuter - Harvard Medical School, Boston, USA
Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding ( Prof David Kuter - Harvard Medical School, Boston, USA )
18 Jun 2026

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026